{"DataElement":{"publicId":"6612622","version":"1","preferredName":"Analgesic Agent Use Name","preferredDefinition":"The name of the analgesic agent used.","longName":"ANALG_AGT_USE_NAME","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"2717533","version":"1","preferredName":"Analgesic Agent Use","preferredDefinition":"information related to use of compounds that alleviate pain without loss of consciousness.","longName":"ANAL_AGT_USE","context":"NIDCR","contextVersion":"1","ObjectClass":{"publicId":"2705028","version":"1","preferredName":"Analgesics","preferredDefinition":"Drugs that reduce pain. These drugs include aspirin, acetaminophen, and ibuprofen.","longName":"C241","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Analgesic Agent","conceptCode":"C241","definition":"Compounds that alleviate pain without loss of consciousness.  Analgesics act by various mechanisms including binding with opioid receptors and decreasing inflammation.  Choice of analgesic may be determined by the type of pain.  These compounds include opioid, non-opioid and adjuvant analgesic agents.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"405C63CB-8CE5-2CFC-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-12-03","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-12-03","modifiedBy":"ONEDATA","dateModified":"2007-12-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2234899","version":"1","preferredName":"Use","preferredDefinition":"Use; put into service; make work or employ (something) for a particular purpose or for its inherent or natural purpose.","longName":"C25340","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Use","conceptCode":"C25340","definition":"A manner, or usual, or accepted practice of using something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9860F29-7486-7421-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-15","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-15","modifiedBy":"ONEDATA","dateModified":"2005-06-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"425E7845-5DB9-4CE7-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-12-28","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-12-28","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6612619","version":"1","preferredName":"Name","preferredDefinition":"The words or language units by which a thing is known.","longName":"6612619v1.0","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"6424136","version":"1","preferredName":"Other","longName":"6424136","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"753441A1-068C-5A23-E053-F662850A6B7A","latestVersionIndicator":"Yes","beginDate":"2018-09-06","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2018-09-06","modifiedBy":"KUMMEROA","dateModified":"2023-02-02","changeDescription":null,"administrativeNotes":"2023.2.2 Alt VM added per ticket request CADSR0002006. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7F85E1C8-39CE-09AA-E053-F662850AC3A2","beginDate":"2019-01-15","endDate":null,"createdBy":"PROSVIROVAB","dateCreated":"2019-01-15","modifiedBy":"ONEDATA","dateModified":"2019-01-15","deletedIndicator":"No"},{"value":"Gabapentin","valueDescription":"Gabapentin","ValueMeaning":{"publicId":"2576881","version":"1","preferredName":"Gabapentin","longName":"2576881","preferredDefinition":"A substance that is being studied as a treatment for relieving hot flashes in women with breast cancer.  It belongs to the family of drugs called anticonvulsants.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gabapentin","conceptCode":"C1108","definition":"A synthetic analogue of the neurotransmitter gamma-aminobutyric acid with anticonvulsant activity. Although its exact mechanism of action is unknown, gabapentin appears to inhibit excitatory neuron activity. This agent also exhibits analgesic properties. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F95E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7F85E1C8-39D8-09AA-E053-F662850AC3A2","beginDate":"2019-01-15","endDate":null,"createdBy":"PROSVIROVAB","dateCreated":"2019-01-15","modifiedBy":"ONEDATA","dateModified":"2019-01-15","deletedIndicator":"No"},{"value":"Tylenol","valueDescription":"Acetaminophen","ValueMeaning":{"publicId":"2575982","version":"1","preferredName":"Acetaminophen","longName":"2575982v1.00","preferredDefinition":"A p-aminophenol derivative with analgesic and antipyretic activities. Although the exact mechanism through which acetaminophen exert its effects has yet to be fully determined, acetaminophen may inhibit the nitric oxide (NO) pathway mediated by a variety of neurotransmitter receptors including N-methyl-D-aspartate (NMDA) and substance P, resulting in elevation of the pain threshold. The antipyretic activity may result from inhibition of prostaglandin synthesis and release in the central nervous system (CNS) and prostaglandin-mediated effects on the heat-regulating center in the anterior hypothalamus.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acetaminophen","conceptCode":"C198","definition":"A p-aminophenol derivative with analgesic and antipyretic activities. Although the exact mechanism through which acetaminophen exert its effects has yet to be fully determined, acetaminophen may inhibit the nitric oxide (NO) pathway mediated by a variety of neurotransmitter receptors including N-methyl-D-aspartate (NMDA) and substance P, resulting in elevation of the pain threshold. The antipyretic activity may result from inhibition of prostaglandin synthesis and release in the central nervous system (CNS) and prostaglandin-mediated effects on the heat-regulating center in the anterior hypothalamus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F5DB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-24","modifiedBy":"MMADDINENI","dateModified":"2023-08-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7F85E1C8-39EC-09AA-E053-F662850AC3A2","beginDate":"2019-01-15","endDate":null,"createdBy":"PROSVIROVAB","dateCreated":"2019-01-15","modifiedBy":"ONEDATA","dateModified":"2019-01-15","deletedIndicator":"No"},{"value":"Toradol","valueDescription":"Ketorolac Tromethamine","ValueMeaning":{"publicId":"6612621","version":"1","preferredName":"Ketorolac Tromethamine","longName":"6612621","preferredDefinition":"The tromethamine salt of ketorolac, a synthetic pyrrolizine carboxylic acid derivative with anti-inflammatory, analgesic and antipyretic properties. Ketorolac tromethamine, a non-selective inhibitor of the cyclooxygenases (COX), inhibits both COX-1 and COX-2 enzymes. This agent exerts its anti-inflammatory effect by preventing conversion of arachidonic acid to prostaglandins at inflammation site mediated through inhibition of COX-2, which is undetectable in most tissues but is up-regulated at the inflammation sites. Since COX-1 is expressed virtually in all tissues, inhibition of COX-1 enzyme by this agent prevents normal state production of prostaglandins, which plays housekeeping roles in the protection of the gastrointestinal tract, regulating renal blood flow, and functioning in platelet aggregation. As a result, inhibition of COX-1 is usually associated with adverse effects such as gastrointestinal toxicity and nephrotoxicity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ketorolac Tromethamine","conceptCode":"C61798","definition":"The tromethamine salt of ketorolac, a synthetic pyrrolizine carboxylic acid derivative with anti-inflammatory, analgesic and antipyretic properties. Ketorolac tromethamine, a non-selective inhibitor of the cyclooxygenases (COX), inhibits both COX-1 and COX-2 enzymes. This agent exerts its anti-inflammatory effect by preventing conversion of arachidonic acid to prostaglandins at inflammation site mediated through inhibition of COX-2, which is undetectable in most tissues but is up-regulated at the inflammation sites. Since COX-1 is expressed virtually in all tissues, inhibition of COX-1 enzyme by this agent prevents normal state production of prostaglandins, which plays housekeeping roles in the protection of the gastrointestinal tract, regulating renal blood flow, and functioning in platelet aggregation. As a result, inhibition of COX-1 is usually associated with adverse effects such as gastrointestinal toxicity and nephrotoxicity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F85E1C8-39F9-09AA-E053-F662850AC3A2","latestVersionIndicator":"Yes","beginDate":"2019-01-15","endDate":null,"createdBy":"PROSVIROVAB","dateCreated":"2019-01-15","modifiedBy":"ONEDATA","dateModified":"2019-01-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7F85E1C8-3A12-09AA-E053-F662850AC3A2","beginDate":"2019-01-15","endDate":null,"createdBy":"PROSVIROVAB","dateCreated":"2019-01-15","modifiedBy":"ONEDATA","dateModified":"2019-01-15","deletedIndicator":"No"},{"value":"Ibuprofen","valueDescription":"Ibuprofen","ValueMeaning":{"publicId":"2578121","version":"1","preferredName":"Ibuprofen","longName":"2578121v1.00","preferredDefinition":"A propionic acid derivate and nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic effects. Ibuprofen inhibits the activity of cyclo-oxygenase I and II, resulting in a decreased formation of precursors of prostaglandins and thromboxanes. This leads to decreased prostaglandin synthesis, by prostaglandin synthase, the main physiologic effect of ibuprofen. Ibuprofen also causes a decrease in the formation of thromboxane A2 synthesis, by thromboxane synthase, thereby inhibiting platelet aggregation. (NCI05)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ibuprofen","conceptCode":"C561","definition":"A propionic acid derivate and nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic effects. Ibuprofen inhibits the activity of cyclo-oxygenase I and II, resulting in a decreased formation of precursors of prostaglandins and thromboxanes. This leads to decreased prostaglandin synthesis, by prostaglandin synthase, the main physiologic effect of ibuprofen. Ibuprofen also causes a decrease in the formation of thromboxane A2 synthesis, by thromboxane synthase, thereby inhibiting platelet aggregation. (NCI05)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE36-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-06","modifiedBy":"MMADDINENI","dateModified":"2023-08-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7F85E1C8-3A1C-09AA-E053-F662850AC3A2","beginDate":"2019-01-15","endDate":null,"createdBy":"PROSVIROVAB","dateCreated":"2019-01-15","modifiedBy":"ONEDATA","dateModified":"2019-01-15","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3260878","version":"1","preferredName":"Concomitant Medication","preferredDefinition":"Concomitant Medication per CDISC CM Definition","longName":"CM","context":"NCIP","contextVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AA1591D7-FC76-D679-E040-BB89AD43495D","latestVersionIndicator":"Yes","beginDate":"2011-08-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-08-09","modifiedBy":"DWARZEL","dateModified":"2017-02-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2229718","version":"1","preferredName":"Name","preferredDefinition":"The words or language units by which a thing is known.","longName":"C42614","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F6EF4E2B-76AE-72C1-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-16","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-05-16","modifiedBy":"ONEDATA","dateModified":"2005-05-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F85E1C8-39B9-09AA-E053-F662850AC3A2","latestVersionIndicator":"Yes","beginDate":"2019-01-15","endDate":null,"createdBy":"PROSVIROVAB","dateCreated":"2019-01-15","modifiedBy":"PROSVIROVAB","dateModified":"2019-06-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Name of drug given:","type":"Preferred Question Text","description":"Name of drug given:","url":null,"context":"COG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F85BDBB-0FF9-5568-E053-F662850A8F06","latestVersionIndicator":"Yes","beginDate":"2019-01-15","endDate":null,"createdBy":"PROSVIROVAB","dateCreated":"2019-01-15","modifiedBy":"KUMMEROA","dateModified":"2023-05-10","changeDescription":"Curated for ANBL1821","administrativeNotes":"2023.5.10 Updated human readable def. ak","unresolvedIssues":null,"deletedIndicator":"No"}}